BioMérieux's Stock Rebounds 2.71% After Hitting a Seven-Year Low at €68.05
The stock of the Lyon-based in vitro diagnostics specialist is regaining some ground this Thursday after a dismal week. Having recorded a new seven-year low at €68.05 at the start of the session, the stock has risen to €70.10, up 2.71% from the previous day's close. The rebound comes as the stock had lost more than a fifth of its value over seven sessions.
A New Historical Low Breached at the Start of the Session
BioMérieux's stock touched €68.05 early in the morning, below the previous low of €68.25 dating from 2019. Thus, the stock erased its seven-year low, extending the movement that began after the company lowered its annual targets on April 23, following a quarterly revenue decline of 3.9% to €984 million. Since this warning, the stock has lost 21% over seven sessions and 28.29% over three months. The market capitalization has fallen by 39.72% over the year. Today's rebound occurs in a Parisian market trending downward, with the CAC 40 losing 1.14% during the session at 7,980 points. Among European comparables, Sartorius Stedim Biotech is up 0.53% and Eurofins Scientific is down 0.45%.
Price Below the Lower Bollinger Band, RSI at 17
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The price at €70.10 remains below the lower Bollinger band set at €77.18, indicating a pronounced oversold condition. The RSI is at 17, a level of selling pressure rarely observed. The moving averages confirm the negative underlying trend: the MM50 at €92.33 and the MM200 at €107.43 are significantly above the current price, with gaps of approximately 31.7% and 53.3% respectively. The support threshold identified at €70.95 was breached at the opening, with the price now just below it. On the calendar, the next official milestone is the publication of the semi-annual results for 2026 scheduled for July 28, followed by the third quarter revenue on November 8.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
